Seeking Alpha

Johnson & Johnson's (JNJ -0.2%) says Simponi, its drug for hard to treat ulcerative colitis...

Johnson & Johnson's (JNJ -0.2%) says Simponi, its drug for hard to treat ulcerative colitis being produced by subsidiary Janssen Biotech, has received FDA approval. The injectable drug is used to induce and maintain remission from the chronic inflammatory bowel disease, which is marked by inflammation and ulceration of the innermost lining of the colon.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|